194 related articles for article (PubMed ID: 28478613)
1. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
Dedić Plavetić N; Jakić-Razumović J; Kulić A; Sirotković-Skerlev M; Barić M; Vrbanec D
Pathol Oncol Res; 2015 Apr; 21(2):315-24. PubMed ID: 25096394
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
5. Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.
Böger C; Behrens HM; Röcken C
J Surg Oncol; 2016 Jan; 113(1):46-54. PubMed ID: 26709194
[TBL] [Abstract][Full Text] [Related]
6. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
7. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
8. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
9. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
12. Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer.
Arun I; Venkatesh S; Ahmed R; Agrawal SK; Leung SCY
APMIS; 2021 Aug; 129(8):489-502. PubMed ID: 34053140
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
[TBL] [Abstract][Full Text] [Related]
14. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.
Liu JJ; Shen R; Chen L; Ye Y; He G; Hua K; Jarjoura D; Nakano T; Ramesh GK; Shapiro CL; Barsky SH; Gao JX
Int J Clin Exp Pathol; 2010 Mar; 3(4):328-37. PubMed ID: 20490325
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.
Khoury T; Zirpoli G; Cohen SM; Geradts J; Omilian A; Davis W; Bshara W; Miller R; Mathews MM; Troester M; Palmer JR; Ambrosone CB
Am J Clin Pathol; 2017 Aug; 148(2):108-118. PubMed ID: 28898983
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations.
Erices-Leclercq M; Lubig S; Förster F; Förster R; Baldus S; Rudlowski C; Schröder L
J Cancer Res Clin Oncol; 2022 Feb; 148(2):441-447. PubMed ID: 33991247
[TBL] [Abstract][Full Text] [Related]
18. Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
Aleskandarany MA; Green AR; Ashankyty I; Elmouna A; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Jul; 158(2):287-95. PubMed ID: 27380874
[TBL] [Abstract][Full Text] [Related]
19. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
[TBL] [Abstract][Full Text] [Related]
20. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
